SCHEMBL6302113

SCHEMBL6302113

CC(=O)N1CCN(C(=O)c2cc3nccc(Cl)c3s2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.46
MAPT P10636 6/20 0.43
TP53 P04637 2/20 0.43
HSP90AA1 P07900 1/20 0.42
SMYD3 Q9H7B4 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPK1 P28482 1/20 0.40
STAT3 P40763 1/20 0.40
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KDR P35968 2/20 0.39
MET P08581 1/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6998891 0.99 CLK1 (0.46) CLK1MAPTTP53HSP90AA1SMYD3
SCHEMBL2537201 0.90 KDM4E (0.50) MAPTTP53HSP90AA1KMT2AKDM4E
SCHEMBL307245 0.88 TP53 (0.52) MAPTTP53SMN1; SMN2MAPK1KDM4E
SCHEMBL198195 0.88 TP53 (0.49) MAPTTP53SMN1; SMN2MEN1KMT2A
SCHEMBL14860038 0.87 TP53 (0.54) MAPTTP53SMN1; SMN2MAPK1NPC1
SCHEMBL2206333 0.85 HPGD (0.51) MAPTTP53SMN1; SMN2MAPK1KDM4E
SCHEMBL6302516 0.84 POLB (0.52) MAPTTP53SMYD3SMN1; SMN2MEN1
SCHEMBL10224379 0.82 MAPT (0.45) MAPTTP53MEN1KMT2AKDR
SCHEMBL10223756 0.81 MAPT (0.52) MAPTTP53SMN1; SMN2NPC1RAB9A
SCHEMBL4710650 0.81 TP53 (0.37) MAPTTP53KDRMETPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6964961-B2 Thiophene derivatives useful as anticancer agents PFIZER INC (US) 2005-11-15 US disclosed
EP-1287001-B1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PROD INC (US) 2004-09-29 EP disclosed
EP-1287001-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS Pfizer Products Inc. (US) 2003-03-05 EP disclosed
US-20020042409-A1 Thiophene derivatives useful as anticancer agents PFIZER PRODUCTS INC. 2002-04-11 US disclosed
WO-2001094353-A1 THIOPHENE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042409-A1 Thiophene derivatives useful as anticancer agents TP53, RCC1, CCNA1 CLK1 3171/4885MAPT 4251/4885TP53 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.